The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01720628

Enrollment

Registered

2012-11-02

Start date

2011-11-30

Completion date

2012-02-29

Last updated

2012-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behçet's Disease

Keywords

Angiogenin, Behçet's disease, bFGF, VEGF

Brief summary

Objectives: Behçet's disease (BD) is a systemic vasculitis. Since vascular endothelial dysfunction plays a prominent role in the pathogenesis of the disease, we considered angiogenic cytokines as an interesting target for investigation in BD. The aim of this study was to investigate the possible role of angiogenin, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD. Design and Methods: Sixty five patients with BD and 21 healthy control subjects were included in the study. Serum angiogenin, bFGF and VEGF concentrations were determined by using in vitro enzyme immunoassay (ELISA) kits according to the manufacturer's instructions.

Interventions

OTHERserum levels of angiogenin, bFGF, VEGF

Behçet's patients

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* age between 18-65 * fulfilling the international diagnostic criteria for Behçet's disease

Exclusion criteria

* to have another systemic disease

Design outcomes

Primary

Measure	Time frame	Description
Serum levels of angiogenin in Behçet's patients with or without ocular involvement	1 year	The median serum angiogenin level was significantly higher in all patients with BD than controls (P=0.001). However there was no statistically significant difference between all patients and patients with or without ocular involvement. The mean serum bFGF and the median serum VEGF levels were higher in patients with ocular involvement than all patients, patients without ocular involvement and controls. But these differences did not reach statistical significance.

Secondary

Measure	Time frame
Serum levels of bFGF in Behçet's patients with or without ocular involvement	1 year

Other

Measure	Time frame
Serum levels of VEGF in Behçet's patients with or without ocular involvement	1 year

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026